Is the regulatory world ready for "nanosimilars"?
This article was originally published in Scrip
Executive Summary
In the beginning there were generics. Then came biosimilars. Now the regulatory world is preparing for the appearance of a new kind of follow-on product: "nanosimilars", or versions of the first generation of nanomedicines, whose patents are on the way to expiry.